Bronchial Asthma
Conditions
Interventions
middle dosage experimental group:Medium dose administration of Guben Qushi granules
low dosage experimental group:Low dose administration of Guben Qushi granules
control group:Guben Qushi Placebo Granules
Sponsors
Guangdong Provincial Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1)Patients who are aged 18–75 years, no gender limitation; (2)Patients who meet the diagnostic criteria of bronchial asthma in a chronic persistent phase with a severity rating of mild to moderate persistence; (3)Asthma Control Test (ACT) scores =19 for uncontrolled asthma; (4)Patients who meet the TCM syndrome of Qi deficiency with Cold Dampness pattern; (5)Patients who sign the written informed consent form.
Exclusion criteria
Exclusion criteria: (1) Patients with severe asthma; (2) Patients with acute or severe asthma within the last 1 month; (3) Patients with respiratory diseases such as chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, and active tuberculosis; (4) Patients with severe or uncontrollable underlying diseases: hepatic insufficiency (ALT or AST = 2 ULN, total bilirubin = 2 ULN), renal insufficiency (serum creatinine > 177 µmol/L or 2 mg/dL), NYHA class III-IV; immunodeficiency, such as malignant tumors, organ or bone marrow transplantation, HIV infection, or taking immunosuppressive agents in the past 3 months; (5) Patients who are unwilling to accept obsevation or unable to co-operate due to mental illness; (6) Patients who are unable to complete pulmonary function tests; (7) Patients who are allergic to the test drug; (8) Pregnant or planning pregnancy, or lactating women; (9) Patients receiving allergen specific immunotherapy or biologically targeted drugs (such as omalizumab, duplizumab, etc.); (10) Patients who are participating in or preparing to participate in other clinical trials during the study period; (11) Subjects with poor compliance and difficulty in completing or complying with the requirements of this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Scores of Asthma Control Test ; | — |
Secondary
| Measure | Time frame |
|---|---|
| Good Control Rate of Asthma;Asthma Control Questionnaire;Mini Asthma Quality of Life Questionnaire ;Cough and Sputum Assessment Questionnaire ;Grading of Asthma Control Level;Dampness Syndrome Scale of Chinese medicine;Syndrome Score Scale of Chinese medicine;Pre-diastolic FEV1 and FVC change values;Acute asthma attacks;Rate of asthma treatment failure;Emergency usage and frequency of SABA; | — |
Countries
China
Contacts
Public ContactLin Lin
Guangdong Provincial Hospital of Chinese Medicine
Outcome results
None listed